RE: Two Months I used to have GAP.V and I could'nt wait for clinical trials so I sold.
I still like the main drug & their technology, I just could'nt wait for the human testing .....
I bought a new Jr Pharma in at "Clinical Stage" small float, and FDA approved drugs .......
fyi,
News Release
Pacific Therapeutics Ltd. to Exhibit at Vancouver Small-Cap Conference
VANCOUVER, BRITISH COLUMBIA- (March 29, 2012) – Pacific Therapeutics Ltd. (PT.CNSX) (the “company”) is pleased to announce that it has been accepted as an exhibitor at the Vancouver Small-Cap Conference to be held on April 10, 2012 at the Vancouver Convention Center.
Pacific Therapeutics Ltd is a clinical stage specialty pharmaceutical company focused on the identification and development of drug candidates to treat diseases of excessive scarring (fibrosis).
The company’s lead drug candidate PTL-202 is a combination of Pentoxifylline (a FDA approved drug used for treating intermittent claudication) and N-Acetyl-Cysteine (NAC) an amino acid and an extremely potent and important antioxidant. PTL-202 is currently being reviewed for initial trials in humans which are expected to commence in 2012.
The Small-Cap Conferences are informative one-day events with 2-3 prominent guest speakers and up to 9 brief corporate presentations from a variety of quality, small-cap Canadian companies.
ABOUT PACIFIC THERAPEUTICS LTD.
TheCompany’s strategy includes reformulating approved drugs to increase efficacy and patient compliance, completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies for fibrosis by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles. The company’s lead drug candidate is PTL-202 a combination of approved drugs focused on treating fibrosis such as Idiopathic Pulmonary Fibrosis and Liver Cirrhosis.
On Behalf of the Board of Directors
/s/ Doug Unwin
Douglas H. Unwin, CEO & President
(604) 738-1049
unwin@pacifictherapeutics.com
www.pacifictherapeutics.com
FORWARD LOOKING STATEMENTS
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Readers should not place undue reliance on the Company’s forward-looking statements, as the Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company’s business, or if the Company’s estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.